The pathophysiology of pancreatic cancer development with GLP-1 RA use is thought to be secondary to chronic low-grade inflammation and proliferative changes leading to KRAS and p53 gene mutations [85]. This evidence concerns the gene GLP1R and pancreatic neoplasm.